Seroba Life Sciences

News, insights, analysis and data

Seroba Life Sciences overview

Stories about Seroba Life Sciences

Picture of the Company

MedLumics pulls in Series B funds

Madrid-based MedLumics, a cardiac device company focused on optically guided minimally invasive instruments, has secured 34.4 million euros in Series B financing. Edmond de Rothschild Investment Partners led the round with participation from other investors that included Seroba Life Sciences, Innogest Capital, Ysios Capital Partners and Caixa Capital Risc. In addition to the funding, EdRIP’s Olivier Litzka, Innogest’s Claudio Rumazza and Seroba’s James Green have been named to MedLumics' board of directors.

Picture of the Company

Prexton Therapeutics raises $31 mln

Prexton Therapeutics said Feb. 7 that it has closed a 29 million euro ($31 million) Series B round led by Forbion Capital Partners and Seroba Life Sciences. Also participating were Merck Ventures (NL), Ysios Capital (ES) and Sunstone Capital (DK). Prexton, of Naarden, the Netherlands, is a biopharmaceutical company developing therapeutic compounds for the treatment of central nervous system conditions.

Picture of the Company

Opsona Therapeutics Raises €18 Million

Opsona Therapeutics, a Dublin, Ireland-based developer of therapeutic and preventative approaches to autoimmune and inflammatory diseases, has raised €18 million in Series B funding. Participants included Novartis Venture Fund, Fountain Healthcare Partners, Inventages Venture Capital and Seroba Kernel Life Sciences.

Seroba Life Sciences contact information

Offices

marker iconMount Herbert Court, 34 Upper Mount Street, Dublin, D02 FT72, Ireland
Showing 1 of 3 Seroba Life Sciences offices

Contacts

NameJob titleLocationEmail
Key Contact
user imageMs. Maud Lazare
Job titlePartner and Head of Investor Relations
LocationDublin, Ireland
Emaillock image-------
user imageMr. Andrew Duignan
Job titlePartner and Chief Financial Officer
LocationDublin, Ireland
Emaillock image----------
user imageMs. Jennifer McMahon
Job titlePartner
LocationDublin, Ireland
Emaillock image-----
user imageMr. Bruno Montanari
Job titlePartner
LocationDublin, Ireland
Emaillock image-----

Seroba Life Sciences funds managed

Closed funds: 4

FundFund sizeClose dateStrategy
Fund sizelock image------
Close dateFeb 2024
Strategylock image-------
Fund sizelock image--------
Close date-
Strategylock image-------
Fund sizelock image--------
Close date-
Strategylock image-----------

Stories that mention Seroba Life Sciences

Side Letter: Brookfield's $15bn potential; Level 20's chair; ESG's lucrative talent war

Brookfield is upping the stakes with its latest private equity flagship. Plus: industry non-profit Level 20 has appointed a new chair and in-demand ESG specialists are making seven-figure salaries. Here's today's brief, for our valued subscribers only.

Coave Therapeutics closes Series B

Coave Therapeutics, a clinical stage biotechnology company, has closed its Series B funding round at $39 million.

Fusion Pharmaceuticals goes public, expects to raise $212m

Fusion Pharmaceuticals, a Hamilton, Ontario-based cancer radiotherapeutics company, has priced its IPO on the NASDAQ at US$17 per share.

VC-backed Fusion Pharmaceuticals seeks $125m from IPO: report

Canadian cancer radiotherapeutics specialist Fusion Pharmaceuticals is looking to raise US$125 million (C$170 million) from its initial public offering on Nasdaq.

Shorla Pharma Limited nabs $8.3m

Shorla Pharma Limited, an Irish specialty pharmaceutical company, has closed $8.3 million in financing.

Canadian VC landscape grew by 3x in 6 years

The North American market saw more than C$6.2 billion flow into the region last year.

Canadian VC begins 2019 with heft as top Q1 deals raise $667 mln

After nine straight years of growth, Canada’s venture capital market showed no signs of slowing down in early 2019. The top 10 first-quarter VC financings drew $667 million from VC funds. While that’s down 28 percent from the $923 million raised by the top 10 deals a year earlier, it exceeds first-quarter results in other recent years. The estimate is based on PE Hub Canada’s list of the largest rounds announced from January through March, supplemented by preliminary data from Refinitiv. It suggests that despite increasing market uncertainty, trends in early 2019 reflect many of the same factors that drove soaring Canadian VC investment activity last year.